Hikma Lines Up US Hybrid Injectable
Deal With Arecor For Undisclosed Drug
Hikma has struck a deal to develop with the UK’s Arecor a ready-to-use injectable that will be filed under the US 505(b)(2) hybrid regulatory pathway.
You may also be interested in...
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.